Zook Anthony P. 4
4 · NEOGENOMICS INC · Filed Jun 3, 2025
Insider Transaction Report
Form 4
Zook Anthony P.
DirectorChief Executive Officer
Transactions
- Tax Payment
Common Stock
2025-06-01−3,424→ 20,166 total - Exercise/Conversion
Common Stock
2025-06-01+12,254→ 23,590 total - Exercise/Conversion
Restricted Stock Unit
2025-06-01−12,254→ 0 totalExercise: $0.00From: 2025-06-01→ Common Stock (12,254 underlying)
Holdings
- 8,353
Stock Option (Right to Buy)
Exercise: $14.82From: 2024-08-10Exp: 2033-08-10→ Common Stock (8,353 underlying) - 729,927
Stock Option (Right to Buy)
Exercise: $10.44Exp: 2035-04-01→ Common Stock (729,927 underlying) - 18,900(indirect: By Trust)
Common Stock
- 8,672
Stock Option (Right to Buy)
Exercise: $13.71From: 2025-06-01Exp: 2034-06-01→ Common Stock (8,672 underlying) - 421,496
Restricted Stock Unit
Exercise: $0.00→ Common Stock (421,496 underlying)
Footnotes (6)
- [F1]Reflects release of restricted stock units that were previously reported on a Form 4.
- [F2]Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the December 1, 2024 vesting of restricted stock.
- [F3]Once vested, the shares of common stock are not subject to expiration.
- [F4]This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.
- [F5]On April 1, 2025, Mr. Zook was granted 729,927 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- [F6]On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.